Oculis Announces Patient Dosing in its First Phase 3 (DIAMOND Study - DIAbetic Macular edema patients ON a Drop) with OCS-01, a Novel, Investigational Topical Eye Drop Treatment for Diabetic Macular Edema (DME)
November 12, 2021 08:00 ET
|
Oculis S.A.
OCS-01 has demonstrated efficacy and safety in a Phase 2b clinical trial in DME offering the potential to become the first topical eye drop and non-invasive treatment for DME Following a positive...
Oculis Appoints Dr. Joanne Chang as Global Chief Medical Officer and Opens Hong Kong Office to broaden its footprint and build a strong Asia/China presence
October 07, 2021 08:00 ET
|
Oculis S.A.
- Dr. J. Chang, former Novartis Global Medical Affairs Head, Ophthalmology, to lead the advancement and expansion of Oculis’ pipeline development and global portfolio management - Dr. J....
Oculis Announces Positive Data from Two Proof-of-Concept Phase 2 Trials with OCS-02, a Novel Topical TNF alpha Antagonist, in Dry Eye Disease and Acute Anterior Uveitis, Presented at ARVO 2021
May 11, 2021 08:00 ET
|
Oculis S.A.
Positive Phase 2a data, presented for the first time, highlights the potential of OCS-02 to become a new treatment in moderate to severe DED and potentially the first personalized therapy in this...
Oculis Announces an Oversubscribed US$57 million Series C Financing
May 04, 2021 08:00 ET
|
Oculis S.A.
New leading international life science investors join current institutional investors with proceeds to: Advance novel, late-stage Investigational ophthalmology drugs OCS-01 and OCS-02 and deliver the...
Oculis to Present Progress in its Portfolio of Novel Topical Treatments for Retinal and Front-of-the-Eye Diseases at Upcoming Investor Conferences
November 24, 2020 08:00 ET
|
Oculis S.A.
LAUSANNE, Switzerland, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of...
Oculis appoints David Jacobs, M.D. as Chief Development Officer adding complementary drug development and regulatory expertise
October 22, 2020 08:00 ET
|
Oculis S.A.
LAUSANNE, Switzerland, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of...
Oculis announces presentation of positive results from Phase 2 trial of OCS-01 in patients with Diabetic Macular Edema (DME) at EURETINA 2020 Virtual
October 05, 2020 08:00 ET
|
Oculis S.A.
The study met its pre-specified efficacy endpoints and showed that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with...
Oculis to present significant corporate and clinical development progress at upcoming biotech and ophthalmology conferences
September 22, 2020 08:00 ET
|
Oculis S.A.
LAUSANNE, Switzerland, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives...
Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01 in Two Ophthalmology Indications
July 27, 2020 08:00 ET
|
Oculis S.A.
Dr. David P. Bingaman Appointed as Vice President, Global Clinical Development LAUSANNE, Switzerland, July 27, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on...